M am
NRNPg6675gMIDTERMgEXAMg(YEARg2022g–
g100/100gPOINTS)gLATESTgUPDATE
1. Whichgofgthegfollowinggaregriskgfactorsgforgneurolepticgmalignantgsyndrome?gSel
ectgallg thatgapplygAge
Rapidgdosegescalation
Parentalgroutegofgadministrationg Hi
ghergpotencygtypicalgantipsychotics
2. AntipsychoticgmedicationsgprovidegD2gblockadegingthegmesocorticalgpathwaygca
usingg whichgofgthegfollowinggeffects?
Reducesgnegativegsymptoms
Increasesgextragpyramidalgsymptoms
g (EPS)gCausesgprolactinemia
Reducesgpositivegsymptoms
3. Phencyclidineg(PCP)gandgKetaminegexertgtheirguniquegbehavioralgeffectsgbygblo
ckingg whichgofgthegfollowinggreceptors?
GABAgtyp
eg recepto
rs
NRNPg6675gMIDTERMgEXAMg(YEARg2022g–
g100/100gPOINTS)gLATESTgUPDATE
about:blank 1/59
,11/22/23,g9:20gP Nrnpg6675g15gweekg6gmidtermgex
M am
Serotonin
g receptor
s
NRNPg6675gMIDTERMgEXAMg(YEARg2022g–
g100/100gPOINTS)gLATESTgUPDATE
about:blank 2/59
,11/22/23,g9:20gP Nrnpg6675g15gweekg6gmidtermgex
M am
Dopaminegreceptors
g NMDAgtypegrecept
ors
4. Thegdiagnosisgusedgtogdescribegagsyndromegcharacterizedgbygspecificgsignsgandg
symptomsgresultinggfromgrecentgingestiongorgexposuregtogagsubstancegisgknowngas
gwhichg ofgthegfollowing?
Substanceg intoxica
tiong Substanceg wi
thdrawalg Substanc
eguseg disordergAn
ygofgtheg above
fi.g Abnormalginvoluntarygmovementsgingagrhythmicgpatterngaffectinggface,gmouth,gton
gue,g jawgisgknowngasgwhichgofgthegfollowing?
Akathisi
g ag Dy
stonig a
NRNPg6675gMIDTERMgEXAMg(YEARg2022g–
g100/100gPOINTS)gLATESTgUPDATE
about:blank 3/59
, 11/22/23,g9:20gP Nrnpg6675g15gweekg6gmidtermgex
M am
Tardivegdyskinesia
g Extrapyramidalgsi
deg effects
6.g Agdeeplygheldgbeliefgdespitegevidencegtogthegcontrary,glastinggatgleastgonegmonth,gwithout
g prominentghallucinations,gwithgfunctionalgimpairmentgthatgrelatesgtogthegdelusionalgsyste.....
Schizophrenia
Delusionalgdisorderg
Briefgpsychoticg disor
der
Schizophreniformgdisorder
NRNPg6675gMIDTERMgEXAMg(YEARg2022g–
g100/100gPOINTS)gLATESTgUPDATE
about:blank 4/59